Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Removal of anti-Galα1,3Gal xenoantibodies with an injectable polymer
Andreas G. Katopodis, … , Rafael Mañez, David White
Andreas G. Katopodis, … , Rafael Mañez, David White
Published December 15, 2002
Citation Information: J Clin Invest. 2002;110(12):1869-1877. https://doi.org/10.1172/JCI16526.
View: Text | PDF
Article

Removal of anti-Galα1,3Gal xenoantibodies with an injectable polymer

  • Text
  • PDF
Abstract

Research Article

Authors

Andreas G. Katopodis, Richard G. Warner, Rudolf O. Duthaler, Markus B. Streiff, Armin Bruelisauer, Olivier Kretz, Birgit Dorobek, Elke Persohn, Hendrik Andres, Alain Schweitzer, Gebhard Thoma, Willy Kinzy, Valerie F.J. Quesniaux, Emanuele Cozzi, Hugh F.S. Davies, Rafael Mañez, David White

×

Figure 5

Options: View larger image (or click on image) Download as PowerPoint
Three rhesus monkeys received a single intravenous injection of 1 mg/kg ...
Three rhesus monkeys received a single intravenous injection of 1 mg/kg [14C]GAS914. Blood was collected at the indicated times. (a) Radioactivity (squares) in whole blood disappeared rapidly from circulation in a biphasic manner. The proportion of radioactivity in plasma versus whole blood was constant (90%), suggesting that GAS914 is not significantly taken up by blood cells (data not shown). Almost no anti-αGal IgM was detected in serum by ELISA after the first bleeding at 5 minutes after injection. There was a slow return of anti-αGal IgM (circles) starting approximately 12 hours after injection. (b) Tissue concentration of total radioactivity 72 hours after administration of 1 mg/kg [14C]GAS914.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts